Opioids relieve pain by binding to receptors in the brain and spinal cord, but those same receptors sit throughout the body, and activating them triggers a long list of unwanted effects. Constipation, drowsiness, nausea, and respiratory depression are the side effects most people hear about, yet opioids also interfere with hormones, immune function, sleep architecture, and even the body’s ability to process pain itself. The range is wider than many patients expect, and several of these effects do not improve with time the way others do.
Constipation and the Gut
If there is one side effect that affects nearly everyone who takes opioids for more than a few days, it is constipation. Unlike most other opioid side effects, the body does not build tolerance to it, so it tends to persist for as long as the medication continues. The reason is straightforward: opioid receptors are densely expressed on the nerve cells that control gut movement and fluid secretion. When opioids bind to those receptors, they quiet the nerves that push food through the intestines and simultaneously reduce water secretion into the colon, making stool harder and slower to move.
Three types of opioid receptors sit on the nerves of the gut wall. The mu and delta receptors suppress the release of the chemical signals that coordinate propulsive contractions and also cut fluid flow into the intestinal lumen. Kappa receptors contribute as well, mainly by dampening neurotransmitter release at nerve terminals.1PubMed Central. Molecular physiology of enteric opioid receptors The net result is a gut that moves sluggishly and absorbs too much water from its contents.2PubMed Central. Opioid-Induced Constipation: Mechanistic Insights, Experimental Models, and Future Perspectives
Because the problem is driven by opioid receptors in the gut itself rather than in the brain, a class of drugs called peripherally acting mu-opioid receptor antagonists (PAMORAs) can block those gut receptors without crossing into the brain and undoing pain relief. Clinical studies have confirmed that these medications relieve opioid-induced constipation while preserving the analgesic benefit of the opioid.3PubMed Central. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety Naloxegol, for instance, works this way and is one of the more commonly prescribed options.4PubMed Central. Clinical utility of naloxegol in the treatment of opioid-induced constipation Over-the-counter laxatives are often the first step, but when they are not enough, PAMORAs fill a gap that standard stool softeners cannot.
Respiratory Depression
The most dangerous acute side effect of opioids is slowed breathing. Opioids reduce the rate and depth of respiration, and in overdose this can stop breathing altogether. The primary target is a cluster of neurons in the brainstem called the preBötzinger Complex, which generates the basic breathing rhythm. Opioids also suppress a nearby region that helps the brain switch between inhaling and exhaling, so breaths become shallower and less frequent at the same time.5PubMed Central. Multi-Level Regulation of Opioid-Induced Respiratory Depression
This is the side effect responsible for most opioid-related deaths. It is dose-dependent and becomes especially dangerous when opioids are combined with other sedating drugs like benzodiazepines or alcohol, which depress breathing through their own pathways. Unlike constipation, some tolerance does develop to respiratory depression over time, which is why patients on stable long-term doses are less likely to stop breathing than someone taking the same dose for the first time. But that tolerance is fragile: if a person stops opioids for even a few days and then resumes at their old dose, the respiratory tolerance they built can be largely gone.
Naloxone reverses respiratory depression by competing with the opioid for the same receptor, effectively reducing the opioid’s grip on the brain’s breathing centers. The tradeoff is that displacing the opioid can also trigger withdrawal symptoms, so dosing naloxone in a real emergency involves balancing two risks.6PubMed Central. Naloxone reversal of fentanyl-induced respiratory depression versus naloxone-induced precipitated withdrawal: an in silico utility model
Tolerance and Paradoxical Pain
With repeated use, the body adapts to opioids, and the same dose produces less pain relief. This pharmacological tolerance develops because the receptors themselves change: they become less responsive, get pulled inside the cell, or are chemically modified in ways that weaken the signal they send.7PubMed Central. Opioid receptor desensitization: mechanisms and its link to tolerance Tolerance to pain relief pushes patients and prescribers toward dose escalation, which increases the risk of every other side effect.
More counterintuitively, opioids can make pain worse. Opioid-induced hyperalgesia is a state in which the nervous system becomes more sensitive to pain, not because the drug is wearing off but because the drug itself has changed how pain signals are processed. Research points to several mechanisms working in parallel. Immune-like cells in the brain and spinal cord called microglia become activated during opioid exposure, and they release inflammatory molecules that amplify pain signaling in nearby neurons.8PubMed. Opioid-induced hyperalgesia: Cellular and molecular mechanisms Animal studies have shown that morphine triggers a specific inflammatory pathway in these cells involving a receptor called TLR4, and blocking that receptor can reverse the heightened pain sensitivity.9PubMed. PAG neuronal NMDARs activation mediated morphine-induced hyperalgesia by HMGB1-TLR4 dependent microglial inflammation
The practical problem is that hyperalgesia looks a lot like tolerance from the patient’s perspective: pain gets worse, and the instinct is to take more medication. But increasing the dose only deepens the cycle. Recognizing the difference usually requires careful clinical assessment, and the main strategy when hyperalgesia is suspected is reducing or rotating opioids rather than escalating them.
Cognitive Effects and Delirium
Drowsiness, mental fogginess, and difficulty concentrating are among the most commonly reported opioid side effects. In older adults, these effects carry outsized consequences because dizziness and impaired balance raise the risk of falls, which in frail patients can lead to fractures and hospitalizations.10PubMed Central. Opioids in the Elderly Patients with Cognitive Impairment: A Narrative Review
Whether long-term opioid use causes lasting cognitive decline is less clear-cut. A systematic review looking at older adults with cancer and chronic pain found that most studies showed no measurable cognitive impairment from opioids, though a few reported worsened attention, language, and memory. Those negative findings tended to cluster in studies where patients were taking higher doses, roughly above the equivalent of 120 milligrams of oral morphine per day.11PubMed. The Effects of Opioids on Cognition in Older Adults With Cancer and Chronic Noncancer Pain: A Systematic Review So at moderate doses, cognition often stays intact, but high-dose or rapid-escalation scenarios are riskier.
Delirium is a separate concern. It involves sudden confusion, disorientation, and sometimes hallucinations, and it is a recognized complication of opioid use across clinical settings. Whether certain opioids carry more delirium risk than others remains debated; reviews have found that the evidence is mixed and no single opioid stands out as clearly safer.12PubMed Central. The Comparative Risk of Delirium with Different Opioids: A Systematic Review
Hormonal Disruption
Opioids suppress the hormonal signals that travel from the brain to the gonads, and the result is a condition often referred to as opioid-induced endocrinopathy. Low testosterone is the most well-recognized consequence, affecting both men and women on long-term opioid therapy.13PubMed. Opioid-induced endocrinopathies Symptoms include fatigue, low libido, erectile dysfunction in men, irregular periods in women, loss of bone density, and depressed mood. Because these symptoms overlap with other conditions and develop gradually, opioid-induced hypogonadism often goes undiagnosed for years.
Other hormonal axes can be affected too. Cortisol production, growth hormone release, and thyroid function have all been reported to change with chronic opioid use, though hypogonadism remains the most consistent and clinically significant finding. Any patient on long-term opioid therapy who develops unexplained fatigue, mood changes, or sexual dysfunction should have their hormone levels checked, because the fix is sometimes as simple as adjusting the opioid regimen or adding hormone replacement.
Immune Suppression
Opioid receptors are found on immune cells, and their activation weakens several lines of defense. Morphine in particular has been shown to suppress natural killer cell activity, impair the ability of macrophages to engulf pathogens, and slow the proliferation of immune cells called lymphocytes.14Exploration of Immunology. Balancing analgesia and immunity: revisiting the immune consequences of opioid therapy Laboratory experiments have confirmed that multiple opioid classes, not just morphine, reduce natural killer cell killing capacity, and that this suppression is reversed when opioid receptor blockers are applied.15PubMed Central. Suppression of Human Natural Killer Cells by Different Classes of Opioids
In patients taking opioids long-term for chronic pain, studies have found measurable shifts in immune cell populations. Compared to untreated controls, long-term opioid users tend to have a lower percentage of natural killer cells and altered inflammatory signaling when their immune cells are stimulated.16PubMed. The effects of long-term opioid treatment on the immune system in chronic non-cancer pain patients: A systematic review The clinical implications are still being studied, but the concern is that chronic opioid use could raise susceptibility to infections and potentially affect cancer surveillance, since natural killer cells play a role in detecting and destroying abnormal cells.
Sleep Disruption
Opioids disrupt the architecture of sleep in ways that go well beyond simple sedation. During both initial and ongoing opioid use, the time spent in REM sleep and deep slow-wave sleep is reduced, meaning the most restorative stages of sleep are cut short.17PubMed. Opioids, sleep architecture and sleep-disordered breathing Patients may feel that they sleep enough hours but wake unrefreshed, which compounds the fatigue already common with opioid use.
Chronic opioid use is also linked to central sleep apnea, a condition where the brain intermittently fails to send the signal to breathe during sleep. About 30% of patients on stable methadone maintenance have been found to have central sleep apnea.18PubMed. Opioids, sleep architecture and sleep-disordered breathing Unlike the more common obstructive sleep apnea, which is caused by a physical blockage of the airway, central sleep apnea stems from the same brainstem depression that causes respiratory slowing while awake. It is a subtler version of the same risk, playing out during sleep when the person has no awareness of it.
Itching
Opioid-induced itching, or pruritus, is one of those side effects that is more annoying than dangerous but can seriously affect quality of life. It is especially common with spinal or epidural opioid administration, though it occurs with oral and intravenous routes too. The itch does not come from a histamine-driven allergic reaction in most cases, which is why antihistamines often do not help much. Instead, multiple pathways are involved, both in the spinal cord and in the skin, and the mechanisms vary depending on the specific opioid and how it is delivered.19PubMed. Mechanisms and treatment of opioid-induced pruritus: Peripheral and central pathways This is a common source of confusion: patients assume the itch means they are allergic to the drug, and sometimes the opioid gets unnecessarily discontinued when the itch could be managed or the patient switched to a different opioid with a lower pruritus profile.
Effects on the Biliary System
A less commonly discussed side effect involves the sphincter of Oddi, the small muscular valve that controls the flow of bile and pancreatic enzymes into the small intestine. Opioids cause this sphincter to contract and spasm, which increases pressure in the bile duct and can cause upper abdominal pain that mimics gallbladder disease. All opioids produce this effect to some degree, though morphine causes the largest pressure increase.20PubMed. Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis Direct measurements have confirmed that morphine raises the pressure inside the common bile duct and increases the frequency of sphincter contractions.21PubMed Central. Effects of narcotic analgesic drugs on human Oddi’s sphincter motility
In people who use opioids chronically, this sphincter dysfunction can become a clinical problem in its own right. A study of opium-addicted patients found that many had dilated bile ducts and delayed drainage, consistent with chronic sphincter dysfunction, even without any gallstone disease. Most improved after a procedure to cut the sphincter open.22PubMed. Sphincter of Oddi dysfunction in patients addicted to opium: an unrecognized entity This side effect rarely makes it onto patient information leaflets, so it is worth knowing about if you are on long-term opioids and developing unexplained upper abdominal pain.
Mood, Reward, and Anhedonia
Opioids interact powerfully with the brain’s reward system, and the mood-related consequences extend beyond the well-known risk of addiction. Anhedonia, the inability to experience pleasure from activities that used to be enjoyable, is a prominent feature in people who become dependent on opioids. Studies of opioid-dependent populations have found that roughly a fifth to nearly half of participants report clinically significant anhedonia, and higher anhedonia scores correlate with stronger cravings and continued use.23PubMed Central. Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder The reward circuitry essentially recalibrates: everyday pleasures become muted while the drug itself remains the strongest source of positive feeling, which helps lock the cycle of dependence in place.
Cardiovascular Risks
Most opioids do not cause major heart problems at standard doses, but methadone is a notable exception. Methadone can prolong the QT interval on an electrocardiogram, a change in the heart’s electrical activity that increases the risk of a potentially fatal irregular rhythm called torsades de pointes.24PubMed Central. Methadone, QTc prolongation and torsades de pointes: Current concepts, management and a hidden twist in the tale? This risk rises with higher doses and when methadone is combined with other drugs that also affect the QT interval. Patients starting methadone, especially at higher doses, are typically monitored with periodic electrocardiograms for this reason.
Prenatal Exposure
When opioids are taken during pregnancy, the newborn can develop neonatal opioid withdrawal syndrome, sometimes still referred to by its older name, neonatal abstinence syndrome. Symptoms include tremors, irritability, feeding difficulties, and excessive crying. Research using brain imaging has found that infants exposed to opioids before birth show altered connectivity between the thalamus and other brain regions, and the degree of those connectivity changes correlates with how severe the withdrawal symptoms are.25PubMed Central. Thalamocortical functional connectivity in infants with prenatal opioid exposure correlates with severity of neonatal opioid withdrawal syndrome Whether these early brain changes translate into long-term developmental differences is still being studied, but the findings underscore why opioid use in pregnancy warrants careful management, typically involving a switch to a safer maintenance medication rather than abrupt discontinuation.
Why Side Effects Vary So Much Between People
Anyone who has compared notes with another opioid user knows that two people on the same drug and dose can have wildly different side-effect profiles. Genetics is one reason. Variations in the gene for the mu opioid receptor itself, OPRM1, have been studied extensively. One well-known variant, rs1799971, changes the structure of the receptor slightly. In a study of breast cancer patients given tramadol after surgery, carriers of at least one copy of this variant had roughly four and a half times the risk of developing constipation compared to non-carriers.26PubMed Central. Association of OPRM1, MIR23B, and MIR107 genetic variability with acute pain, chronic pain and adverse effects after postoperative tramadol and paracetamol treatment in breast cancer Variants in genes that regulate small RNA molecules also influenced nausea risk in the same study, suggesting that the genetic picture involves more than just the receptor itself.
Genome-wide studies looking for addiction-linked variants have flagged the same OPRM1 rs1799971 variant as well as a variant in the BDNF gene, though neither reached statistical significance as an independent predictor of opioid use disorder in a broader analysis.27PubMed Central. Genetic Variants Linked to Opioid Addiction: A Genome-Wide Association Study The genetics of opioid response are complex and still being pieced together, but the practical takeaway is real: one person’s “mild side effects” can be another person’s intolerable experience, and genes are part of the explanation.
Rare Complications of Specialized Delivery
Most opioid side effects relate to the drug’s systemic action, but certain delivery methods introduce their own risks. Intrathecal pumps, which deliver opioids directly into the spinal fluid for severe chronic pain, can occasionally produce granulomas at the tip of the catheter. These are inflammatory masses that form around the catheter tip and can compress the spinal cord, causing new neurological symptoms including weakness and numbness. Treatment typically requires surgical removal of the granuloma and catheter, though in cases where surgery is not feasible, stopping the intrathecal morphine and switching to spinal cord stimulation has been used as an alternative.28PubMed Central. The Management of Unresectable Intrathecal Catheter-Tip-Associated Granuloma Using Morphine Therapy Cessation and Spinal Cord Stimulation
The Search for Opioids with Fewer Side Effects
Researchers have been trying for decades to separate opioid pain relief from opioid side effects, and one of the most active lines of investigation focuses on how the receptor signals inside the cell after an opioid binds to it. The mu opioid receptor can activate different internal pathways depending on the drug that hits it. Evidence from genetically modified animal models suggests that the pathway involving G proteins is mainly responsible for pain relief, while a separate pathway involving a scaffolding molecule called beta-arrestin contributes to side effects like respiratory depression and constipation.29PubMed Central. Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics This concept, sometimes called biased agonism, has driven efforts to design opioids that preferentially activate the G protein pathway while avoiding the arrestin pathway.30PubMed Central. Quantitative Systems Pharmacology and Biased Agonism at Opioid Receptors: A Potential Avenue for Improved Analgesics
The results in living animals have been encouraging, but translating the concept into approved drugs has proven difficult. Oliceridine, the first biased agonist to receive FDA approval, showed some reduction in gastrointestinal side effects in trials, but the advantage over traditional opioids was more modest than hoped. The underlying biology is messier than the clean two-pathway model suggests, and it is becoming clear that the relationship between signaling bias and clinical side effects is not as simple as early studies implied. Still, the broader program of designing opioids around specific signaling profiles remains one of the most promising avenues for making opioid therapy safer in the long run.